DermatologyResearch Phase

Eyeseryl (Acetyl Tetrapeptide-5)

Topical

Overview

Acetyl Tetrapeptide-5 is a synthetic tetrapeptide modified with an acetyl group to improve stability and cellular uptake. The peptide is proposed to reduce periorbital edema by modulating capillary permeability and enhancing lymphatic drainage, potentially through downregulation of pro-inflammatory cytokines such as interleukin-1.

Mechanism of Action

Its application is focused on reduction of under-eye puffiness and fluid accumulation..

Research Summary & Key Findings

In vitro studies on endothelial cell monolayers have demonstrated reduced permeability and decreased inflammatory marker expression. A small clinical trial reported subjective improvement in periorbital edema after four weeks, though the study lacked control groups and has not been reproduced in major peer-reviewed dermatology journals.

Clinical Status

Research Phase

Eyeseryl (Acetyl Tetrapeptide-5) is in the research phase with limited clinical data in humans. Current evidence is primarily derived from preclinical (animal or in vitro) studies.

Administration Routes

Topical

Related Peptides in Dermatology

Find a Provider

Find a verified provider who offers Eyeseryl (Acetyl Tetrapeptide-5) therapy in your area.

Browse Provider Map

Find a Pharmacy

Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply Eyeseryl (Acetyl Tetrapeptide-5).

Pharmacy Directory

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol.